WASHINGTON — Senator Ron Johnson (R-Wis.) has launched an investigation into the Food and Drug Administration’s (FDA) recent rejections of treatments for rare diseases, raising concerns about the agency’s decision-making process and potential roadblocks to life-altering therapies. The senator is seeking access to the complete response letters – official notifications of rejection – sent by the FDA to pharmaceutical companies developing treatments for conditions like ataxia and Sanfilippo syndrome.
Johnson expressed concern that the reasons cited in these letters may be unduly restrictive, describing them as “nitpicky things” that could unnecessarily delay or prevent access to potentially beneficial treatments. His inquiry comes amid growing frustration from patient advocacy groups and some lawmakers who believe the FDA is being overly cautious, hindering innovation and denying hope to individuals with limited therapeutic options.
The investigation specifically focuses on the FDA’s rationale for denying approval, aiming to determine whether the agency’s standards are appropriately balanced with the urgent needs of patients suffering from rare and often fatal conditions. This scrutiny arrives as the FDA faces increasing pressure to expedite the review of treatments for diseases affecting slight populations, where the traditional clinical trial model can be challenging.
Sanfilippo syndrome, a rare genetic disorder that primarily affects children, is one of the conditions at the center of this debate. According to Global Genes, the FDA recently declined to approve Ultragenyx Pharmaceutical’s UX111, an investigational gene therapy for Sanfilippo syndrome type A. The decision, announced in July 2025, was attributed to manufacturing issues, though the FDA reportedly did not find fault with the clinical data submitted by Ultragenyx.
This isn’t an isolated incident. Ultragenyx resubmitted its application for UX111 in January 2026, anticipating another six-month review period, as reported by the San Francisco Business Times. The company believes the manufacturing concerns are “readily addressable.” The FDA’s decisions have as well impacted other companies developing therapies for conditions like Duchenne Muscular Dystrophy and advanced melanoma, prompting a coalition of patient advocacy groups to call for a meeting with FDA Commissioner Dr. Martin Makary to discuss these concerns, as noted in a USA Today opinion piece.
Concerns Over FDA’s Regulatory Approach
Senator Johnson’s investigation builds on existing criticism of the FDA’s regulatory processes, particularly regarding rare diseases. Advocates argue that the agency’s stringent requirements, designed for more common conditions, can be overly burdensome for companies developing treatments for small patient populations. This can lead to higher development costs and a reduced incentive for investment in these areas.
The issue extends beyond Sanfilippo syndrome. As STAT News reported on March 10, 2026, Johnson is requesting complete response letters for a range of rare disease treatments, including those for ataxia. This broader inquiry suggests a systemic concern about the FDA’s approach to evaluating and approving therapies for conditions affecting a limited number of patients.
What’s Next for the Investigation?
Senator Johnson has requested the FDA provide the requested complete response letters, which will allow his office to analyze the specific reasons for the rejections and assess whether the agency’s concerns are justified. The senator has not set a specific timeline for the completion of the investigation, but has indicated a commitment to uncovering the factors influencing the FDA’s decisions. The outcome of this investigation could potentially lead to legislative changes aimed at streamlining the approval process for rare disease treatments and ensuring that patients have access to innovative therapies.
The FDA has not yet publicly responded to Senator Johnson’s request. Although, the agency is likely to face increased scrutiny from Congress and patient advocacy groups as it navigates the complex challenges of regulating treatments for rare diseases. The debate highlights the ongoing tension between ensuring patient safety and fostering innovation in the development of life-saving therapies.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the FDA’s role in approving treatments for rare diseases? Share your comments below.
